Granting the wishes of anti-abortion groups, the Trump administration announced it will end fetal tissue research by government scientists; Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell a powerful fentanyl spray; Medicaid enrollees who would potentially be subject to Medicaid work requirements are likely to face barriers to employment.
The Trump administration said Wednesday that they have discontinued all internal research that involves fetal tissue, putting an end to fetal tissue research by government scientists. The announcement was welcome news to anti-abortion activists, as fetal tissue is obtained through elective abortions. According to a statement from HHS, external fetal-tissue projects that receive government funding will continue, but new or renewed grant applications will require approval from an ethics advisory board. Scientists have spoken out against the announcement, saying that fetal tissue research has been essential to developing life-saving therapies.
Opioid manufacturer Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell Susbys, a fentanyl spray meant for patients with cancer with severe pain, reported the Associated Press. The settlement comes a month after Insys founder John Kapoor and other former executives of the company were convicted of bribing doctors to prescribe the drug. As part of the agreement, the company will enter a 5-year deferred prosecution agreement with the Justice Department and its operating subsidiary will plead guilty to 5 counts of mail fraud.
Medicaid enrollees who would potentially be subject to Medicaid work requirements implemented by their state are more likely to face barriers to sustained employment compared with privately insured adults, according to a brief from the Urban Institute. Barriers include low education level, health problems, limited transportation and internet access, criminal history, and residence in high-unemployment or high-poverty neighborhoods. Less than 1 in 6 potentially affected Medicaid enrollees reported working at least 20 hours per week for nearly all weeks in the past year, compared with more than 3 in 5 privately insured adults.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More